14,360 results match your criteria Hepatocellular Carcinoma Imaging


Preoperative radiomics nomogram for microvascular invasion prediction in hepatocellular carcinoma using contrast-enhanced CT.

Eur Radiol 2019 Feb 15. Epub 2019 Feb 15.

Key Laboratory of Molecular Imaging, Chinese Academy of Sciences, Beijing, People's Republic of China.

Objectives: To develop and validate a radiomics nomogram for preoperative prediction of microvascular invasion (MVI) in patients with hepatocellular carcinoma (HCC).

Methods: The study included 157 patients with histologically confirmed HCC with or without MVI, and 110 patients were allocated to the training dataset and 47 to the validation dataset. Baseline clinical factor (CF) data were collected from our medical records, and radiomics features were extracted from the artery phase (AP), portal venous phase (PVP) and delay phase (DP) of preoperatively acquired CT in all patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00330-018-5985-yDOI Listing
February 2019

Whole tumor ablation of locally recurred hepatocellular carcinoma including retained iodized oil after transarterial chemoembolization improves progression-free survival.

Eur Radiol 2019 Feb 15. Epub 2019 Feb 15.

Department of Radiology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea.

Objectives: To evaluate and compare clinical outcomes of two different radiofrequency ablation (RFA) methods for locally recurred hepatocellular carcinoma (LrHCC) after locoregional treatment.

Methods: Our institutional review board approved this study with a waiver of informed consent. A total of 313 patients previously treated with transarterial chemoembolization (TACE) (n = 167) and RFA (n = 146) with a single LrHCC ≤ 3 cm was included from five tertiary referral hospitals. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00330-018-5993-yDOI Listing
February 2019

Wilson's Disease: Clinical Practice Guidelines of the Indian National Association for Study of the Liver, the Indian Society of Pediatric Gastroenterology, Hepatology and Nutrition, and the Movement Disorders Society of India.

J Clin Exp Hepatol 2019 Jan-Feb;9(1):74-98. Epub 2018 Sep 3.

Department of Pediatrics and Pediatric Liver GI and Nutrition Center and Mowat Labs, King's College Hospital, London, UK.

Clinical practice guidelines for Wilson's disease (WD) have been published by the American Association for the Study of Liver Diseases and European Association for the Study of the Liver in 2008 and 2012, respectively. Their focus was on the hepatic aspects of the disease. Recently, a position paper on pediatric WD was published by the European Society of Pediatric Gastroenterology Hepatology and Nutrition. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jceh.2018.08.009DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6363961PMC
September 2018

Long Term Survival of Patients Undergoing TIPS in Budd-Chiari Syndrome.

J Clin Exp Hepatol 2019 Jan-Feb;9(1):56-61. Epub 2018 Mar 1.

Consultant, Department of Vascular and Interventional Radiology, Tan Tock Seng Hospital, Singapore.

Background: There has been significant improvement in understanding the etiology and management of Budd-Chiari Syndrome (BCS). Patients with chronic or acute-on-chronic BCS need radiological interventions in the form of angioplasty, hepatic vein/inferior vena cava stenting or Transjugular Intrahepatic Portosystemic Shunt (TIPS). Data regarding the long term follow up of patients undergoing TIPS is limited. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jceh.2018.02.008DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6363956PMC
March 2018
1 Read

MRI texture analysis for differentiation of malignant and benign hepatocellular tumors in the non-cirrhotic liver.

Heliyon 2018 Nov 30;4(11):e00987. Epub 2018 Nov 30.

Institute of Interventional and Diagnostic Radiology, University Hospital Zurich and University of Zurich, Zurich, Switzerland.

Purpose: To find potentially diagnostic texture analysis (TA) features and to evaluate the diagnostic accuracy of two-dimensional (2D) magnetic resonance (MR) TA for differentiation between hepatocellular carcinoma (HCC) and benign hepatocellular tumors in the non-cirrhotic liver in an exploratory MR-study.

Materials And Methods: 108 non-cirrhotic patients (62 female; 41.5 ± 18. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.heliyon.2018.e00987DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6286882PMC
November 2018

Induction of GNMT by 1,2,3,4,6-penta-O-galloyl-beta-D-glucopyranoside through proteasome-independent MYC downregulation in hepatocellular carcinoma.

Sci Rep 2019 Feb 13;9(1):1968. Epub 2019 Feb 13.

Center for Infectious Disease and Cancer Research (CICAR), Kaohsiung Medical University, Kaohsiung, Taiwan.

Glycine-N-methyl transferase (GNMT) a tumor suppressor for hepatocellular carcinoma (HCC) plays a crucial role in liver homeostasis. Its expression is downregulated in almost all the tumor tissues of HCC while the mechanism of this downregulation is not yet fully understood. Recently, we identified 1,2,3,4,6-penta-O-galloyl-beta-D-glucopyranoside (PGG) as a GNMT promoter enhancer compound in HCC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41598-018-37292-1DOI Listing
February 2019

Cancer Res 2019 Feb 13. Epub 2019 Feb 13.

Cancer Center, University of Hawaii at Manoa.

Studies involving transcriptomics have revealed multiple molecular subtypes of hepatocellular carcinoma (HCC). PET/CT has also identified distinct molecular imaging subtypes, including those with increased and decreased choline metabolism as measured by tissue uptake of the radiopharmaceutical 18F-flurocholine. Gene signatures reflecting the molecular heterogeneity of HCC may identify the biological and clinical significance of these imaging subtypes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-18-3837DOI Listing
February 2019
9.329 Impact Factor

Comparison of international guidelines for noninvasive diagnosis of hepatocellular carcinoma: 2018 update.

Clin Mol Hepatol 2019 Feb 14. Epub 2019 Feb 14.

Department of Radiology, Seoul National University Hospital, Seoul, Korea.

The goal of this review is to present the similarities and differences among the latest guidelines for noninvasive diagnosis of hepatocellular carcinoma (HCC) of American Association for the Study of Liver Disease (AASLD), European Association for the Study of the Liver (EASL), Liver Imaging Reporting and Data System (LI-RADS), Asian Pacific Association for the Study of the Liver (APASL), and Korean Liver Cancer Association- National Cancer Center (KLCA-NCC) of Korea. In 2018, major guideline updates have been proposed by the AASLD, EASL and KLCA-NCC; AASLD newly incorporated LI-RADS into their HCC diagnostic algorithm. The AASLD and EASL guidelines now include magnetic resonance imaging (MRI) using hepatobiliary contrast media as a first-line diagnostic test in addition to dynamic computed tomography and MRI using extracellular contrast media and the KLCA-NCC and EASL guidelines also include contrast-enhanced ultrasound as a second-line diagnostic test. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3350/cmh.2018.0090DOI Listing
February 2019

Fluoxetine Induces Apoptosis through Extrinsic/Intrinsic Pathways and Inhibits ERK/NF-κB-Modulated Anti-Apoptotic and Invasive Potential in Hepatocellular Carcinoma Cells In Vitro.

Int J Mol Sci 2019 Feb 11;20(3). Epub 2019 Feb 11.

Department of Medical Imaging and Radiological Sciences, Central Taiwan University of Science and Technology, Taichung 406, Taiwan.

The aim of the present study was to verify the effects of fluoxetine on dysregulation of apoptosis and invasive potential in human hepatocellular carcinoma (HCC) SK-Hep1 and Hep3B cells. Cells were treated with different concentrations of fluoxetine for different times. MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide) assays were used for testing the effects of fluoxetine on cell viability. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/ijms20030757DOI Listing
February 2019
1 Read

Bioengineered Let-7c Inhibits Orthotopic Hepatocellular Carcinoma and Improves Overall Survival with Minimal Immunogenicity.

Mol Ther Nucleic Acids 2019 Jan 24;14:498-508. Epub 2019 Jan 24.

Department of Biochemistry & Molecular Medicine, UC Davis School of Medicine, Sacramento, CA 95817, USA. Electronic address:

Hepatocellular carcinoma (HCC) remains a leading cause of cancer-related deaths, warranting better therapies. Restoration of tumor-suppressive microRNAs depleted in hepatocellular carcinoma represents a new therapeutic strategy. Herein, we sought to identify a potent microRNA (miRNA) agent that could alleviate HCC tumor burden and improve survival. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.omtn.2019.01.007DOI Listing
January 2019
1 Read

The Molecular Chaperone HSP70 Controls Liver Cancer Initiation and Progression by Regulating Adaptive DNA-Damage and MAPK/ERK Signaling Pathways.

Mol Cell Biol 2019 Feb 11. Epub 2019 Feb 11.

Molecular Chaperone Biology, Medical College of Georgia, Georgia Cancer Center, Department of Medicine, and Department of Radiology and Imaging, Augusta University, Augusta, GA 30912

Delineating the mechanisms that drive hepatic injury and hepatocellular carcinoma (HCC) progression is critical for development of novel treatments for recurrent and advanced HCC, but also diagnostic and preventive strategies. Heat shock protein 70 (HSP70) acts in concert with several co-chaperones and nucleotide exchange factors and plays an essential role in protein quality control that increases survival by protecting cells against environmental stressors. Specifically, HSP70-mediated response has been implicated in the pathogenesis of cancer, but the specific mechanisms by which HSP70 may support malignant cell transformation remains to be fully elucidated. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1128/MCB.00391-18DOI Listing
February 2019

Surveillance Rate and its Impact on Survival of Hepatocellular Carcinoma Patients in South Korea: A Cohort Study.

Cancer Res Treat 2019 Feb 12. Epub 2019 Feb 12.

Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea.

Purpose: Though regular surveillance of hepatocellular carcinoma (HCC) for high-risk patients is widely recommended, its rate and effectiveness are not clear. The aim of this study is to investigate the actual rate of HCC surveillance and its related factors and to clarify its impact on survival in a Korean HCC cohort.

Materials And Methods: From 2012 to 2015, 319 newly diagnosed HCC patients were prospectively enrolled at a tertiary hospital. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4143/crt.2018.430DOI Listing
February 2019

Combined locoregional-immunotherapy for liver cancer.

J Hepatol 2019 Feb 6. Epub 2019 Feb 6.

Center for Interventional Oncology, Radiology and Imaging Sciences, NIH Clinical Center & Center for Cancer Research, National Institutes of Health, United States; NCI CCR Liver Cancer Program, United States.

Locoregional therapies are commonly used to treat patients with hepatocellular carcinoma. It has been noted for many years that locoregional therapies may have additional systemic effects other than simple tumor elimination. Immunological "side effects" have been described in response to locoregional therapies in animal studies and also in patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jhep.2019.01.027DOI Listing
February 2019
1 Read

Does Drug-Eluting Bead TACE Enhance the Local Effect of IRE? Imaging and Histopathological Evaluation in a Porcine Model.

Cardiovasc Intervent Radiol 2019 Feb 8. Epub 2019 Feb 8.

Department of Diagnostic and Interventional Radiology, RWTH Aachen University Hospital, Pauwelsstrasse 30, 52074, Aachen, Germany.

Objectives: We conducted an in vivo trial on swine to compare the ablation volumes of irreversible electroporation (IRE) followed by drug-eluting beads transarterial chemoembolization (DEB-TACE) versus IRE only.

Materials And Methods: Nine swine underwent CT-guided IRE in one liver lobe and IRE immediately followed by DEB-TACE in a different liver lobe. For DEB-TACE, 100-300 µm beads (DC-Beads) were loaded with 50 mg doxorubicin. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00270-019-02181-1DOI Listing
February 2019
1 Read

Pathogenesis of hypothyroidism-induced NAFLD: Evidence for a distinct disease entity?

Dig Liver Dis 2019 Jan 2. Epub 2019 Jan 2.

Section of Endocrinology, Diabetes and Metabolism, Department of Medicine, University and Azienda Ospedaliera Universitaria Integrata of Verona, Verona, Italy.

Nonalcoholic fatty liver disease (NAFLD), the most common liver disease worldwide, may be associated with primary hypothyroidism. However, the pathogenesis underlying such an association is complex and not completely understood. Here, we specifically discuss the pathogenic mechanisms potentially involved in hypothyroidism-induced NAFLD. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.dld.2018.12.014DOI Listing
January 2019
1 Read

Hyperprogressive disease in hepatocellular carcinoma with immune checkpoint inhibitor use: a case series.

Immunotherapy 2019 Feb;11(3):167-175

Department of Oncologic Imaging, National Cancer Centre, Singapore, 169610, Singapore.

Immune checkpoint inhibitors (ICIs) have demonstrated promising results in a variety of advanced cancer types. The phenomenon of hyperprogressive disease (HPD) has only been documented in recent years, however, there have been no reports of HPD in hepatocellular carcinoma. We present a case series of six patients with advanced hepatocellular carcinoma treated with ICIs who demonstrated rapid radiological progression, this was confirmed by comparing tumor growth rates before and during treatment with HPD defined as tumor growth rate ≥2. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/imt-2018-0126DOI Listing
February 2019

Association Between Sarcopenia and AFP Level in Patients Undergoing Liver Transplantation for Hepatocellular Carcinoma.

J Surg Res 2019 Feb 2;238:10-15. Epub 2019 Feb 2.

Department of Radiology, University of Kentucky College of Medicine, Lexington, Kentucky.

Background: Sarcopenia is one of the most common complications of cirrhosis. Liver transplantation (LT) is the treatment of choice for patients with early-stage hepatocellular carcinoma (HCC) that are unsuitable for resection.

Methods: We performed a retrospective analysis of 163 patients transplanted at our institution with HCC from 1998 to 2016. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jss.2019.01.007DOI Listing
February 2019
2 Reads

Identification of the Potential Metabolic Pathways Involved in the Hepatic Tumorigenesis of Rat Diethylnitrosamine-Induced Hepatocellular Carcinoma via H NMR-Based Metabolomic Analysis.

Biomed Res Int 2019 2;2019:9367082. Epub 2019 Jan 2.

Key Laboratory of Imaging Diagnosis and Minimally Invasive Intervention Research, the Fifth Affiliated Hospital of Wenzhou Medical University/Affiliated Lishui Hospital of Zhejiang University/The Central Hospital of Zhejiang Lishui, Lishui 323000, China.

The systemic investigation of the metabolic pathways associated with the hepatic tumorigenesis is important to discover novel biomarkers and identify the potential pathogenesis. Here, the H nuclear magnetic resonance- (H NMR-) based metabolomic analysis was used to monitor the whole process of rat diethylnitrosamine-induced HCC. Intraperitoneal administration of diethylnitrosamine (DEN) was used to induce primary HCCs in male Sprague-Dawley rats. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2019/9367082DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6334336PMC
January 2019
2 Reads

YAP and TAZ Heterogeneity in Primary Liver Cancer: An Analysis of Its Prognostic and Diagnostic Role.

Int J Mol Sci 2019 Feb 1;20(3). Epub 2019 Feb 1.

Department of Imaging and Pathology, Translational Cell and Tissue Research, KU Leuven and University Hospitals Leuven, 3000 Leuven, Belgium.

Primary liver cancer comprises a diverse group of liver tumors. The heterogeneity of these tumors is seen as one of the obstacles to finding an effective therapy. The Hippo pathway, with its downstream transcriptional co-activator Yes-associated protein (YAP) and transcriptional co-activator with PDZ-binding motif (TAZ), has a decisive role in the carcinogenesis of primary liver cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/ijms20030638DOI Listing
February 2019
1 Read

Preliminary results of the Phase 1 Lip-Re I clinical trial: biodistribution and dosimetry assessments in hepatocellular carcinoma patients treated with Re-SSS Lipiodol radioembolization.

Eur J Nucl Med Mol Imaging 2019 Feb 4. Epub 2019 Feb 4.

Department of Nuclear Medicine, Cancer Institute Eugène Marquis, Avenue de la Bataille Flandres-Dunkerque, CS 44229, 35042, Rennes, cedex, France.

Purpose: This study sought to provide preliminary results on the biodistribution and dosimetry following intra-arterial liver injection of Re-SSS Lipiodol on hepatocellular carcinoma patients included in the Phase I Lip-Re 1 study.

Methods: Results of the first six patients included are reported. Analysis of the Re-SSS Lipiodol biodistribution was based on planar scintigraphic and tomoscintigraphic (SPECT) studies performed at 1, 6, 24, 48, and 72 h post-administration. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00259-019-04277-9DOI Listing
February 2019
1 Read

Polyethylene Glycol Epirubicin-Loaded Transcatheter Arterial Chemoembolization Procedures Utilizing a Combined Approach with 100 and 200 μm Microspheres: A Promising Alternative to Current Standards.

J Vasc Interv Radiol 2019 Jan 31. Epub 2019 Jan 31.

Vascular and Interventional Radiology Unit, Department of Diagnostic Service, Sapienza University of Rome, Rome, Italy.

Purpose: To report clinical effectiveness, toxicity profile, and prognostic factors of combined 100 μm ± 25 and 200 μm ± 50 epirubicin-loaded polyethylene glycol (PEG) microsphere drug-eluting embolic transcatheter arterial chemoembolization protocol in patients with hepatocellular carcinoma.

Materials And Methods: In this prospective, single-center, single-arm study with 18 months of follow-up, 36 consecutive patients (mean age 69.9 y ± 10. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S10510443183164
Publisher Site
http://dx.doi.org/10.1016/j.jvir.2018.10.026DOI Listing
January 2019
2 Reads

Current status of imaging biomarkers predicting the biological nature of hepatocellular carcinoma.

Jpn J Radiol 2019 Feb 2. Epub 2019 Feb 2.

Department of Radiology, Kanazawa University Graduate School of Medical Sciences, 13-1 Takaramachi, Kanazawa, Ishikawa, 920-8640, Japan.

Hepatocellular carcinoma (HCC) is heterogeneous in terms of its biological nature. Various factors related to its biological nature, including size, multifocality, macroscopic morphology, grade of differentiation, macro/microvascular invasion, bile duct invasion, intra-tumoral fat and molecular factors, and their value as prognostic imaging biomarkers have been reported. And recently, genome-based molecular HCC classification correlated with clinical outcome has been elucidated. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11604-019-00817-3DOI Listing
February 2019

Volumetric quantitative histogram analysis using diffusion-weighted magnetic resonance imaging to differentiate HCC from other primary liver cancers.

Abdom Radiol (NY) 2019 Feb 2. Epub 2019 Feb 2.

Department of Radiology, Icahn School of Medicine at Mount Sinai, 1 Gustave L. Levy Place, New York, NY, 10029, USA.

Objective: To evaluate the ability of volumetric quantitative apparent diffusion coefficient (ADC) histogram parameters and LI-RADS categorization to distinguish hepatocellular carcinoma (HCC) from other primary liver cancers [intrahepatic cholangiocarcinoma (ICC) and combined HCC-ICC].

Methods: Sixty-three consecutive patients (44 M/19F; mean age 62 years) with primary liver cancers and pre-treatment MRI including diffusion-weighted imaging (DWI) were included in this IRB-approved single-center retrospective study. Tumor type was categorized pathologically. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00261-019-01906-7DOI Listing
February 2019
1 Read

CXCR6 Inhibits Hepatocarcinogenesis by Promoting Natural Killer T and CD4+ T cell-Dependent Control of Senescence.

Gastroenterology 2019 Jan 30. Epub 2019 Jan 30.

Department of Medicine III, RWTH-University Hospital Aachen, Aachen, Germany; Department of Hepatology/Gastroenterology, Charité University Medical Center, Berlin, Germany. Electronic address:

Background & Aims: Inflammation in the liver provokes fibrosis but inflammation is also important for tumor surveillance. Inhibitors of chemokine pathways, such as CXCL16 and CXCR6 regulation of lymphocyte trafficking, are being tested as anti-fibrotic agents, but their effects on development of hepatocellular carcinoma (HCC) are unclear. We assessed the roles of CXCR6-dependent immune mechanisms in hepatocarcinogenesis. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00165085193034
Publisher Site
http://dx.doi.org/10.1053/j.gastro.2019.01.247DOI Listing
January 2019
3 Reads

Imaging post-stereotactic body radiation therapy responses for hepatocellular carcinoma: typical imaging patterns and pitfalls.

Abdom Radiol (NY) 2019 Feb 1. Epub 2019 Feb 1.

Joint Department of Medical Imaging, University Health Network, Mount Sinai Hospital and Women's College Hospital, University of Toronto, 585 University Avenue, Toronto, ON, M5G 2N2, Canada.

Stereotactic body radiation therapy (SBRT) has increased utility in the management of hepatocellular carcinoma (HCC) ranging from local therapy in early-stage HCC not suitable for other focal therapies to end-stage HCC. As the indications for the use of SBRT in HCC expand, diagnostic imaging is being increasingly used to assess response to treatment. The imaging features of tumor response do not parallel those of other focal therapies such as radiofrequency ablation or trans-arterial chemoembolization that immediately devascularize the tumor. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00261-019-01901-yDOI Listing
February 2019

Identification of extrahepatic metastasis of hepatocellular carcinoma using indocyanine green fluorescence imaging.

Photodiagnosis Photodyn Ther 2019 Jan 29. Epub 2019 Jan 29.

Department of Hepatobiliary Surgery, Affiliated Hospital, Southwest Medical University, Luzhou 646000, China. Electronic address:

Background/purpose: Intraoperative fluorescence imaging with indocyanine green (ICG) plays a significant role in the identification of hepatocellular carcinoma (HCC) during Hepatectomy. Despite that, few researchers have reported using ICG fluorescence imaging to detect extrahepatic metastases. Herein, we report the successful application of ICG fluorescence imaging in the detection of extrahepatic metastatic lesions from primary liver cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.pdpdt.2019.01.031DOI Listing
January 2019
1 Read

Population-based assessment of the national comprehensive cancer network recommendations for baseline imaging of hepatocellular carcinoma.

Med Oncol 2019 Feb 1;36(3):26. Epub 2019 Feb 1.

Department of Oncology, University of Calgary, Tom Baker Cancer Centre, 1331 29 ST NW, Calgary, AB, T2N 4N2, Canada.

This analysis aims to evaluate the performance characteristics of alternative baseline imaging thresholds in a cohort of hepatocellular carcinoma (HCC) patients from the Surveillance, Epidemiology, and End Results (SEER) database. HCC patients within the SEER database (2010-2015) who had complete information on clinical T and N stages as well as complete information on metastatic sites were eligible for the current study. Various performance characteristics associated with baseline imaging were investigated, including specificity, sensitivity, positive likelihood ratio (LR), negative LR, number needed to investigate (NNI), negative predictive value (NPV), positive predictive value (PPV), and accuracy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12032-019-1248-2DOI Listing
February 2019

[Hepatocellular carcinomas and their mimics].

Authors:
H-P Fischer D Goltz

Pathologe 2019 Feb;40(1):101-118

Pathologisches Institut Koblenz, Franz-Weis-Str. 13, Koblenz, Deutschland.

High resolution cross-sectional imaging techniques means that even small, well-differentiated hepatocellular tumors can also be diagnosed with biopsy. In cirrhotic liver tissue, macroregenerative and dysplastic nodules must be discriminated from hepatocellular cancer (HCC). In non-cirrhotic liver tissue the differential diagnosis includes hepatocellular adenoma, macroregeneratory nodules, fibrolamellar carcinoma, as well as primary tumors and metastases. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00292-018-0565-0DOI Listing
February 2019
7 Reads

Serum biomarkers and risk of hepatocellular carcinoma recurrence after liver transplantation.

World J Hepatol 2019 Jan;11(1):50-64

Department of Internal Medicine, Hospital Universitario Puerta de Hierro-Majadahonda, Majadahonda 28222, Spain.

Liver transplantation (LT) is the only potentially curative treatment for selected patients with cirrhosis and hepatocellular carcinoma (HCC) who are not candidates for resection. When the Milan criteria are strictly applied, 75% to 85%of 3- to 4-year actuarial survival rates are achieved, but up to 20% of the patients experience HCC recurrence after transplantation. The Milan criteria are based on the preoperative tumor macromorphology, tumor size and number on computed tomography or magnetic resonance imaging that neither correlate well with posttransplant histological study of the liver explant nor accurately predict HCC recurrence after LT, since they do not include objective measures of tumor biology. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4254/wjh.v11.i1.50DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6354126PMC
January 2019

Hepatocellular carcinoma in non-cirrhotic liver: A comprehensive review.

World J Hepatol 2019 Jan;11(1):1-18

Division of Gastroenterology and Hepatology, Case Western Reserve University/MetroHealth Medical Center, Cleveland, OH 44109, the United States.

Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer, which in turns accounts for the sixth most common cancer worldwide. Despite being the 6 most common cancer it is the second leading cause of cancer related deaths. HCC typically arises in the background of cirrhosis, however, about 20% of cases can develop in a non-cirrhotic liver. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4254/wjh.v11.i1.1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6354117PMC
January 2019
1 Read

The CCR2 Macrophage Subset Promotes Pathogenic Angiogenesis for Tumor Vascularization in Fibrotic Livers.

Cell Mol Gastroenterol Hepatol 2018 Oct 18;7(2):371-390. Epub 2018 Oct 18.

Department of Medicine III, Rheinisch-Westfälische Technische Hochschule Aachen, Aachen, Germany. Electronic address:

Background & Aims: Hepatocellular carcinoma (HCC) typically arises in fibrotic or cirrhotic livers, which are characterized by pathogenic angiogenesis. Myeloid immune cells, specifically tumor-associated macrophages (TAMs), may represent potential novel therapeutic targets in HCC, complementing current ablative or immune therapies. However, the detailed functions of TAM subsets in hepatocarcinogenesis have remained obscure. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S2352345X183015
Publisher Site
http://dx.doi.org/10.1016/j.jcmgh.2018.10.007DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6357791PMC
October 2018
2 Reads

Differentiating between hepatocellular carcinoma and intrahepatic cholangiocarcinoma using contrast-enhanced MRI features: a systematic review and meta-analysis.

Authors:
M-W You S J Yun

Clin Radiol 2019 Jan 28. Epub 2019 Jan 28.

Department of Radiology, Kyung Hee University Hospital at Gangdong, Kyung Hee University School of Medicine, 892 Dongnam-ro, Gangdong-gu, Seoul 05278, Republic of Korea. Electronic address:

Aim: To identify magnetic resonance imaging (MRI) features for differentiating hepatocellular carcinoma (HCC) from intrahepatic cholangiocarcinoma (IHCC) and summarise their diagnostic accuracy.

Materials And Methods: PubMed and EMBASE were searched for studies that employed MRI features to differentiate HCC from IHCC. Overlapping descriptors used to denote the same imaging finding in different studies were subsumed under a single feature. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.crad.2018.12.016DOI Listing
January 2019
1 Read

Hepatoid adenocarcinoma in the peritoneal cavity: Two case reports.

Medicine (Baltimore) 2019 Feb;98(5):e14226

Department of Radiology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.

Rationale: Hepatoid adenocarcinoma (HAC) is a rare extrahepatic adenocarcinoma that histologically resembles hepatocellular carcinoma (HCC). HAC of peritoneal cavity can present as a solitary mass or disseminated nodules indicating different treatment.

Patient Concerns: In this study, we present the cases of a 29-year-old man and a 64-year-old woman who suffered from HAC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MD.0000000000014226DOI Listing
February 2019

Design of the Texas Hepatocellular Carcinoma Consortium Cohort Study.

Am J Gastroenterol 2019 Jan 23. Epub 2019 Jan 23.

Section of Gastroenterology and Hepatology, Department of Medicine, Baylor College of Medicine and Michael E. DeBakey Veterans Affairs Medical Center, Houston, Texas, USA.

Objectives: The Texas Hepatocellular Carcinoma Consortium cohort study investigates risk factors of hepatocellular carcinoma (HCC) and biomarkers for early HCC detection in patients with liver cirrhosis.

Methods: Adult patients with liver cirrhosis are enrolled at 5 clinical centers from 3 cities in Texas, with a target of 5,000 patients. Clinical history, risk factor questionnaires, liver imaging, laboratory data, and blood samples were collected at enrollment and at each 6-month follow-up visit. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.14309/ajg.0000000000000068DOI Listing
January 2019
2 Reads

Detection of Hyperacute Reactions of Desacetylvinblastine Monohydrazide in a Xenograft Model Using Intravoxel Incoherent Motion DWI and R2* Mapping.

AJR Am J Roentgenol 2019 Jan 30:1-10. Epub 2019 Jan 30.

1 Medical Imaging Center, The First Affiliated Hospital of Jinan University, No. 613, Huangpu Rd West, Tianhe District, Guangzhou, Guangdong 510630, China.

Objective: This study aimed to investigate the feasibility of intravoxel incoherent motion (IVIM) DWI and R2* (transverse relaxation rate) mapping to monitor the hyperacute therapeutic efficacy of desacetylvinblastine monohydrazide (DAVLBH) on an experimental hepatocellular carcinoma mouse model within 24 hours.

Materials And Methods: Forty-four mice were implanted with hepatocellular carcinoma and divided into three random groups. A treatment group and a control group underwent IVIM-DWI and R2* mapping examinations before and after a single injection of DAVLBH or saline at 1, 2, 4, and 24 hours. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2214/AJR.18.20517DOI Listing
January 2019

Value of Perfusion Parameters for Differentiating Hepatocellular Carcinoma and Liver Metastasis With Hypervascularity and a Normal Hepatic Background on Contrast-Enhanced Ultrasound Imaging.

J Ultrasound Med 2019 Jan 30. Epub 2019 Jan 30.

Department of Ultrasound, Zhongshan Hospital, Fudan University, Shanghai, China.

Objectives: To retrospectively evaluate the value of contrast-enhanced ultrasound (CEUS) perfusion parameters in the differential diagnosis of hepatocellular carcinomas (HCCs) and metastatic liver tumors (MLTs) with hypervascularity.

Methods: Sixty-seven HCCs and 55 MLTs with arterial homogeneous/heterogeneous hyperenhancement on CEUS imaging and a normal liver background were included in this retrospective study. Six CEUS perfusion parameters were compared between HCCs and MLTs with different sizes and HCC differentiations: rise time (RT), time to peak (TTP), mean transit time, wash-out time (WT), maximum intensity (IMAX), and area under the curve (AUC). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jum.14957DOI Listing
January 2019
1.532 Impact Factor

Irreversible Electroporation for Unresectable Hepatocellular Carcinoma: Initial Experience.

Cardiovasc Intervent Radiol 2019 Jan 29. Epub 2019 Jan 29.

Department of Radiodiagnosis and Imaging, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, 160012, India.

Purpose: To evaluate the efficacy and safety of irreversible electroporation (IRE) in the treatment of unresectable hepatocellular carcinoma (HCC).

Materials And Methods: A retrospective study was conducted from September 2014 to June 2017. A total of 21 HCCs in 21 patients with cirrhosis were treated with IRE. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00270-019-02164-2DOI Listing
January 2019

MRI assessment of hepatocellular carcinoma after locoregional therapy.

Insights Imaging 2019 Jan 29;10(1). Epub 2019 Jan 29.

Radiology Department, Faculty of Medicine, Ain Shams University and MR Unit of Misr Radiology Center, Cairo, Egypt.

Liver cirrhosis and hepatocellular carcinoma (HCC) constitute one of the major causes of morbidity, mortality, and high health care costs worldwide. Multiple treatment options are available for HCC depending on the clinical status of the patient, size and location of the tumor, and available techniques and expertise. Locoregional treatment options are multiple. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13244-019-0690-1DOI Listing
January 2019
1 Read

Hepatocellular Carcinoma versus Other Hepatic Malignancy in Cirrhosis: Performance of LI-RADS Version 2018.

Radiology 2019 Jan 29:181995. Epub 2019 Jan 29.

From the Department of Radiology (Y.Y.K., M.J.K., C.A.) and Biostatistics Collaboration Unit, Department of Biomedical Systems Informatics (E.H.K., Y.H.R.), Severance Hospital, Yonsei University College of Medicine, Seodaemun-gu Yonsei-ro 50-1, Seoul 03722, Republic of Korea.

Purpose To evaluate the diagnostic accuracy of the Liver Imaging Reporting and Data System (LI-RADS) version 2018 for differentiating between hepatocellular carcinoma (HCC) and other (hepatic) malignancy (OM) in patients with liver cirrhosis. Materials and Methods From 2008 to 2017, 55 patients with untreated OM and liver cirrhosis were eligible for this retrospective case-control study (mean age, 58 years ± 10 [standard deviation] [range, 32-79 years], with 45 men [mean age, 58 years ± 11] and 10 women [mean age, 62 years ± 7]). Control subjects consisted of 165 treatment-naive patients with HCC and liver cirrhosis (mean age, 58 years ± 10 [range, 29-80 years], with 134 men [mean age, 58 years ± 9] and 31 women [mean age, 59 years ± 11]). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1148/radiol.2019181995DOI Listing
January 2019

Hepatocellular carcinoma surveillance: Eastern and Western perspectives.

Ultrasonography 2018 Oct 28. Epub 2018 Oct 28.

Department of Radiology, University Hospitals Paris Nord Val de Seine, Clichy, France.

Eastern and Western guidelines for the management of hepatocellular carcinoma (HCC) are known to significantly differ on many points, because they reflect different diagnostic and therapeutic approaches to this cancer. Importantly, these guidelines are primarily consensus-driven when it comes to surveillance, both in term of the tests used and surveillance program design. The main difference between East and West lies in clinical practice, as several Eastern countries implement coordinated and systematic surveillance programs, while most Western countries rely on individual adherence to surveillance recommendations. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.14366/usg.18043DOI Listing
October 2018

The effect of anti-CTLA4 treatment on peripheral and intra-tumoral T cells in patients with hepatocellular carcinoma.

Cancer Immunol Immunother 2019 Jan 28. Epub 2019 Jan 28.

Gastrointestinal Malignancies Section, Thoracic and GI Oncology Branch, Center for Cancer Research, National Cancer Institute (NCI), National Institutes of Health (NIH), Building 10, Room 3B43, Bethesda, MD, 20892, USA.

Background: Checkpoint inhibitors have recently been approved for the treatment of patients with hepatocellular carcinoma (HCC). However, biomarkers, which will help identify patients responding to therapy, are missing. We recently tested the combination of anti-CTLA4 treatment (tremelimumab) with loco-regional therapy in patients with HCC and reported a partial response rate of 26%. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00262-019-02299-8DOI Listing
January 2019
1 Read

1Gold Nanoparticles Application in Liver Cancer.

Photodiagnosis Photodyn Ther 2019 Jan 23. Epub 2019 Jan 23.

Department of Medical Biotechnology, School of Advanced Medical Sciences and Technologies, Shiraz University of Medical Sciences, Shiraz, Iran. Electronic address:

Studies have shown that hepatocellular carcinoma (HCC) (the most important types of liver cancer) is the fifth most common cancer, and the third cause of mortality, globally. Although major progress has been made in the treatment and diagnosis of this disease, its eradication remains limited. Consequently, discovering new diagnosis and treatment methods is important. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.pdpdt.2019.01.027DOI Listing
January 2019
1 Read

Efficacy and Safety of Microwave Ablation (MWA) for Hepatocellular Carcinoma (HCC) in Difficult Anatomical Sites in Egyptian Patients with Liver Cirrhosis

Asian Pac J Cancer Prev 2019 Jan 25;20(1):295-301. Epub 2019 Jan 25.

Department of Endemic Medicine, Faculty of Medicine, Cairo University, Cairo, Egypt. Email:

Background and aim: Imaging guided microwave ablation (MWA) for hepatocellular carcinoma (HCC) has become a widely used method over recent years. Tumors close to the diaphragm, gastrointestinal tract, gallbladder, pancreas, hepatic hilum and major bile duct or vessels are generally considered relative contraindications for microwave ablation. This study was conducted to assess the effectiveness and safety of ultrasonography-guided MWA in treating patients with HCC in difficult anatomical sites in comparison to those in conventional sites. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.31557/APJCP.2019.20.1.295DOI Listing
January 2019
1 Read

Secalonic Acid-F, a Novel Mycotoxin, Represses the Progression of Hepatocellular Carcinoma via MARCH1 Regulation of the PI3K/AKT/β-catenin Signaling Pathway.

Molecules 2019 Jan 22;24(3). Epub 2019 Jan 22.

Department of Imaging, Binzhou Medical University, Yantai 264003, China.

Liver cancer is a very common and significant health problem. Therefore, powerful molecular targeting agents are urgently needed. Previously, we demonstrated that secalonic acid-F (SAF) suppresses the growth of hepatocellular carcinoma (HCC) cells (HepG2), but the other anticancer biological functions and the underlying mechanism of SAF on HCC are unknown. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/molecules24030393DOI Listing
January 2019
2 Reads

68Ga-DOTANOC PET/CT Detects Multifocal Hepatocellular Carcinoma.

Clin Nucl Med 2019 Mar;44(3):238-239

From the Nuclear Medicine, Department of Experimental, Diagnostic and Specialty Medicine, and.

Ga-DOTANOC PET/CT confirmed somatostatin receptor (SR) expression in hypervascularized liver lesions suggestive of neuroendocrine tumor that was later diagnosed as hepatocellular carcinoma (HCC). Being highly vascularized on CT, HCC lesions may mimic neuroendocrine tumors. Although HCC is not included among current indications for SR-PET/CT imaging, it may represent a pitfall in image interpretation when studying neuroendocrine tumor patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/RLU.0000000000002426DOI Listing

Identification of Arterial Hyperenhancement in CT and MRI in Patients with Hepatocellular Carcinoma: Value of Unenhanced Images.

Korean J Radiol 2019 Feb;20(2):236-245

Statistics and Data Center, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.

Objective: According to the current guidelines, arterial hyperenhancement for diagnosis of hepatocellular carcinoma (HCC) is determined using the arterial phase only. We investigated the optimal definition of arterial hyperenhancement in patients with HCC using computed tomography (CT) and magnetic resonance imaging (MRI).

Materials And Methods: The Institutional Review Board approved this retrospective study. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3348/kjr.2018.0339DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6342759PMC
February 2019
1.807 Impact Factor

CT/MR LI-RADS 2018: clinical implications and management recommendations.

Abdom Radiol (NY) 2019 Jan 22. Epub 2019 Jan 22.

Department of Radiology, Thomas Jefferson University, Philadelphia, PA, USA.

Unique among solid organ tumors, hepatocellular carcinoma (HCC), may be diagnosed by imaging alone, without the need for biopsy. The Liver Imaging Reporting and Data System (LI-RADS) was developed to provide high-specificity diagnosis of HCC based on imaging while also standardizing the assessment and reporting of the entire spectrum of lesions and pseudolesions encountered in patients at risk for this malignancy. In this pictorial review, we discuss management recommendations associated with CT/MR LI-RADS observations. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00261-018-1868-6DOI Listing
January 2019

The Role of Nrf2 in Liver Disease: Novel Molecular Mechanisms and Therapeutic Approaches.

Front Pharmacol 2018 8;9:1428. Epub 2019 Jan 8.

Department of Liver Surgery, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.

Oxidative stress and inflammation are the most important pathogenic events in the development and progression of liver diseases. Nuclear erythroid 2-related factor 2 (Nrf2) is the master regulator of the cellular protection induction of anti-inflammatory, antioxidant, and cyto-protective genes expression. Multiple studies have shown that activation or suppression of this transcriptional factor significantly affect progression of liver diseases. Read More

View Article

Download full-text PDF

Source
https://www.frontiersin.org/article/10.3389/fphar.2018.01428
Publisher Site
http://dx.doi.org/10.3389/fphar.2018.01428DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6331455PMC
January 2019
4 Reads

Efficacy and safety of high-intensity focused ultrasound ablation for hepatocellular carcinoma by changing the acoustic environment: microbubble contrast agent (SonoVue) and transcatheter arterial chemoembolization.

Int J Hyperthermia 2019 Jan 22:1-9. Epub 2019 Jan 22.

b Clinical Center for Tumor Therapy of the Second Affiliated Hospital of Chongqing Medical University , Chongqing , China.

Objective: To compare efficacy and safety of microbubble contrast agent (SonoVue) and transcatheter arterial chemoembolization (TACE) in combination with high-intensity focused ultrasound (HIFU) for treatment of patients with hepatocellular carcinoma (HCC).

Methods: According to our inclusion criteria, we retrospectively reviewed 52 patients with HCCs, and divided them into SonoVue group and TACE group. Tumors were examined by enhanced magnetic resonance imaging. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/02656736.2018.1558290DOI Listing
January 2019
1 Read

Pretreatment prediction of immunoscore in hepatocellular cancer: a radiomics-based clinical model based on Gd-EOB-DTPA-enhanced MRI imaging.

Eur Radiol 2019 Jan 21. Epub 2019 Jan 21.

Department of Medical Ultrasonics, Institute of Diagnostic and Interventional Ultrasound, The First Affiliated Hospital of Sun Yat-sen University, 58 Zhong Shan Road 2, Guangzhou, 510080, China.

Objectives: Immunoscore evaluates the density of CD3+ and CD8+ T cells in both the tumor core and invasive margin. Pretreatment prediction of immunoscore in hepatocellular cancer (HCC) is important for precision immunotherapy. We aimed to develop a radiomics model based on gadolinium-ethoxybenzyl-diethylenetriamine (Gd-EOB-DTPA)-enhanced MRI for pretreatment prediction of immunoscore (0-2 vs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00330-018-5986-xDOI Listing
January 2019
1 Read